1361229-74-4Relevant academic research and scientific papers
TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
, (2021/12/08)
The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.
Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds
Hou, Zengye,Nakanishi, Isao,Kinoshita, Takayoshi,Takei, Yoshinori,Yasue, Misato,Misu, Ryosuke,Suzuki, Yamato,Nakamura, Shinya,Kure, Tatsuhide,Ohno, Hiroaki,Murata, Katsumi,Kitaura, Kazuo,Hirasawa, Akira,Tsujimoto, Gozoh,Oishi, Shinya,Fujii, Nobutaka
, p. 2899 - 2903 (2012/06/01)
Protein kinase CK2 (CK2) is a ubiquitous serine/threonine protein kinase for hundreds of endogenous substrates. CK2 has been considered to be involved in many diseases, including cancers. Herein we report the discovery of a novel ATP-competitive CK2 inhibitor. Virtual screening of a compound library led to the identification of a hit 2-phenyl-1,3,4-thiadiazole compound. Subsequent structural optimization resulted in the identification of a promising 4-(thiazol-5-yl)benzoic acid derivative.
